AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05220969 — intervention group
Intervention type: GENETIC
Intervention: Total Genotype Risk Score
Description: A total genotype risk score has been generated based on the results of previously observed genetic association studies
Study NCT03620617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry supplement
Description: During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
Study NCT03498066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-blockers withdrawal
Description: withdrawal of all type of betablockers
Study NCT03498066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of the Betablockers (βB) treatment
Description: Use Betablockers treatment
Study NCT04242550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive Function- Enhanced CBT for BED (EF-BED+CBT)
Description: EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.
Study NCT04242550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED.
Study NCT04242550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED.
Study NCT02020187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise on a cycle-ergometer
Description: Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
Study NCT02806531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: two doses enterovirus 71 vaccine
Description: Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
Study NCT00809848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.075%
Description: AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
Study NCT00809848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.05%
Description: AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
Study NCT00809848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.025%
Description: AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
Study NCT00809848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
Study NCT00809848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-210669 vehicle ophthalmic solution
Description: AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
Study NCT00994929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neumega (Oprelvekin, Interleukin 11, IL-11)
Description: 25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
Study NCT03378661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Benznidazole tablet
Study NCT03378661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224
Description: E1224 capsules
Study NCT03378661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224 Placebo
Description: E1224 matched placebo capsules
Study NCT03378661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E1224 Placebo
Description: E1224 matched placebo capsules
Study NCT03378661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole Placebo
Description: Benznidazole matched placebo tablets
Study NCT03886636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuroscience pain education
Description: A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
Study NCT03886636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
Study NCT03886636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercises
Description: All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
Study NCT03886636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercises
Description: All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
Study NCT03378661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benznidazole Placebo
Description: Benznidazole matched placebo tablets
Study NCT03633136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic video education
Description: Solid Organ Transplantation: An Educational Mini-Series for Patients consists of 6 videos ranging in length between 3 and 23 minutes, and has been developed according to best practice for designing education for patients with end-stage renal disease pursuing transplant. Each video outlines a subsequent stage of the transplant process, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives keep the content relevant and culturally inclusive. The educational intervention was developed with experts in medication adherence, video education, motivational psychology, cultural education (First Nations perspective), healthcare providers, and most importantly patients.
Study NCT03813667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention FamPALcare
Description: The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the Conversation Ready pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use teach-back processes to ensure that FamPALcare discussions are clear.
Study NCT02160990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5 mcg exenatide subcutaneously twice daily for 30 days
Study NCT02160990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo subcutaneously twice daily for 30 days
Study NCT03024879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Study NCT03024879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00100061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice
Description: liquid juice taken daily
Study NCT00100061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry Juice
Description: Taken orally
Study NCT00100061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cranberry juice
Description: Placebo comparitor
Study NCT02718560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing
Description: Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
Study NCT02296281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Study NCT04644003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP1
Description: STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor
Study NCT04644003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication (capsule and tablet) identical in appearance to active medication
Study NCT01749774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Study NCT05538871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Survey + Physical exam
Description: Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests
Study NCT04568421 — intervention group
Intervention type: DRUG
Intervention: Immunosuppressive Agents
Description: Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
Study NCT04812730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2D versus 3D analysis of EOS stereo radiographic analysis
Description: The use of EOS stereo radiographic analysis and health related quality of life scores to measure the distance of the center of acoustic meati in the transversal plane with respect to the gravity line
Study NCT04812730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Static versus dynamic analysis
Description: The use of clinical postural tests and instrumented movement analysis to evaluate the importance of muscle fatigue and compensation mechanisms
Study NCT04812730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre- versus postoperative analysis
Description: The use of EOS stereo radiographic imaging and motion analysis to understand the compensation mechanisms in trunk, pelvis and lower limbs and the correlation between primary and secondary mechanisms.
Study NCT04812730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reliability of the dynamic evaluation
Description: Repeated measurements of the different aspects of the dynamic evaluation protocol (strenght measurements of trunk muscles, balance evaluation and movement analysis) will serve to evaluate the test-retest reliability and intra-rater reliability of the different protocols
Study NCT04120441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Mentoring/Intervention
Description: Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions.
Study NCT01364571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
Study NCT01364571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonization swab sample
Description: Colonization swabs will be collected from all subjects at various time points throughout the study.
Study NCT02528604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
Study NCT02528604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker and AV node ablation
Description: Permanent pacemaker implant followed by AV node ablation
Study NCT02528604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DC Cardioversion
Description: Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
Study NCT02528604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Study NCT04668807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Medical Device
Description: Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
Study NCT04668807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional transmission system
Description: Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
Study NCT02231697 — intervention group
Intervention type: OTHER
Intervention: Non-interventional, retrospective medical chart review
Description: Non-interventional, retrospective medical chart review
Study NCT00708279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation
Description: Participant will be evaluated and treated for somatic dysfunction utilizing osteopathic manipulation once a week for 3 weeks, then once every 3 weeks for three more visits; a total of 6 interventions in 3 months.
Study NCT02924454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
Study NCT02924454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous lipid emulsion
Description: Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
Study NCT02924454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride 0.9% solution - lipid emulsion dummy
Description: Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
Study NCT02924454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride 0.9% solution - metoprolol dummy
Description: Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
Study NCT02831153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
Study NCT01026662 — intervention group
Intervention type: PROCEDURE
Intervention: Ablation and skin resurfacing
Description: Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
Study NCT01026662 — intervention group
Intervention type: DEVICE
Intervention: eMatrixCO2
Study NCT03916380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit Juice
Description: Single 8 ounce administration of oral grapefruit juice
Study NCT02234570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
Study NCT01364571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine mid dose
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
Study NCT01364571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
Study NCT01364571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine high dose
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
Study NCT01364571 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
Study NCT01364571 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw
Description: Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
Study NCT01364571 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonization swab sample
Description: Colonization swabs will be collected from all subjects at various time points throughout the study.
Study NCT00291525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-X valve using reduced anticoagulation
Description: Valve replacement with antiplatelet agents or lowered warfarin
Study NCT00291525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-X Valve with Standard warfarin Therapy
Description: Valve replacement with standard dosage warfarin
Study NCT02234570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline administered with an oral dosing syringe. Group 1- Group 6
Study NCT00635817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 11.25 mg
Description: Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
Study NCT00635817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 30 mg
Description: Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
Study NCT01333514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspart
Description: Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
Study NCT01333514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspart- Insulin
Description: 0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
Study NCT00819910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 8mg daily for 12 weeks
Study NCT00819910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone 8mg daily for 12 weeks
Study NCT00819910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Rosiglitazone)
Description: Placebo (Rosiglitazone) 8mg daily for 12 weeks
Study NCT00819910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Rosiglitazone)
Description: Placebo (Rosiglitazone) 8mg daily for 12 weeks
Study NCT00819910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Fenofibrate)
Description: Placebo (Fenofibrate) 145 mg daily for 12 weeks
Study NCT00819910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Fenofibrate)
Description: Placebo (Fenofibrate) 145 mg daily for 12 weeks
Study NCT00819910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate 145 mg daily for 12 weeks
Study NCT02052882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: romiplostim
Study NCT02592655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Tourniquet
Description: Automated pneumatic tourniquet, applied to middle upper thigh.